AR053246A1 - Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales - Google Patents

Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales

Info

Publication number
AR053246A1
AR053246A1 ARP060101724A ARP060101724A AR053246A1 AR 053246 A1 AR053246 A1 AR 053246A1 AR P060101724 A ARP060101724 A AR P060101724A AR P060101724 A ARP060101724 A AR P060101724A AR 053246 A1 AR053246 A1 AR 053246A1
Authority
AR
Argentina
Prior art keywords
expression
sparc
gene
promoter
isolated dna
Prior art date
Application number
ARP060101724A
Other languages
English (en)
Spanish (es)
Inventor
Osvaldo Luis Podhajcer
Eduardo Gustavo Alfr Cafferata
Maria Veronica Lopez
Diego Luis Viale
Original Assignee
Fundacion Inst Leloir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Inst Leloir filed Critical Fundacion Inst Leloir
Priority to ARP060101724A priority Critical patent/AR053246A1/es
Publication of AR053246A1 publication Critical patent/AR053246A1/es
Priority to AT07776311T priority patent/ATE550943T1/de
Priority to NZ572350A priority patent/NZ572350A/en
Priority to PCT/US2007/010196 priority patent/WO2007127347A2/en
Priority to AU2007243252A priority patent/AU2007243252B2/en
Priority to US12/298,743 priority patent/US8436160B2/en
Priority to ES07776311T priority patent/ES2384736T3/es
Priority to EP07776311A priority patent/EP2048954B1/en
Priority to JP2009507816A priority patent/JP5215290B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP060101724A 2006-04-28 2006-04-28 Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales AR053246A1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ARP060101724A AR053246A1 (es) 2006-04-28 2006-04-28 Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales
AT07776311T ATE550943T1 (de) 2006-04-28 2007-04-26 Isoliertes dna-fragment des menschlichen sparc- promoters und seine verwendung
NZ572350A NZ572350A (en) 2006-04-28 2007-04-26 An isolated dna fragment of the sparc human promoter and its use
PCT/US2007/010196 WO2007127347A2 (en) 2006-04-28 2007-04-26 An isolated dna fragment of the sparc human promoter and its use
AU2007243252A AU2007243252B2 (en) 2006-04-28 2007-04-26 An isolated DNA fragment of the SPARC human promoter and its use
US12/298,743 US8436160B2 (en) 2006-04-28 2007-04-26 Isolated DNA fragment of the SPARC human promoter and its use for driving the expression of an heterologous gene in tumor cells
ES07776311T ES2384736T3 (es) 2006-04-28 2007-04-26 Un fragmento aislado de ADN del promotor humano de SPARC y su uso
EP07776311A EP2048954B1 (en) 2006-04-28 2007-04-26 An isolated dna fragment of the sparc human promoter and its use
JP2009507816A JP5215290B2 (ja) 2006-04-28 2007-04-26 Ｓｐａｒｃヒトプロモーターの単離されたｄｎａ断片及び腫瘍細胞において異種の遺伝子の発現を駆動するためのその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP060101724A AR053246A1 (es) 2006-04-28 2006-04-28 Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales

Publications (1)

Publication Number Publication Date
AR053246A1 true AR053246A1 (es) 2007-04-25

Family

ID=38006653

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101724A AR053246A1 (es) 2006-04-28 2006-04-28 Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales

Country Status (9)

Country Link
US (1) US8436160B2 (enExample)
EP (1) EP2048954B1 (enExample)
JP (1) JP5215290B2 (enExample)
AR (1) AR053246A1 (enExample)
AT (1) ATE550943T1 (enExample)
AU (1) AU2007243252B2 (enExample)
ES (1) ES2384736T3 (enExample)
NZ (1) NZ572350A (enExample)
WO (1) WO2007127347A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304281B1 (es) * 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
US9056133B2 (en) * 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer
WO2020172509A1 (en) * 2019-02-21 2020-08-27 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
EP4172208A2 (en) 2020-06-26 2023-05-03 Sorrento Therapeutics, Inc. Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772993A (en) * 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
WO2000072679A1 (en) * 1999-05-28 2000-12-07 University Of Virginia Patent Foundation Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
CA2530748A1 (en) * 2003-06-24 2005-02-24 Johns Hopkins University Methylated gene biomarkers for detecting cancer
WO2007000020A1 (en) 2005-06-29 2007-01-04 Compumedics Limited Sensor assembly with conductive bridge

Also Published As

Publication number Publication date
ATE550943T1 (de) 2012-04-15
JP2009535031A (ja) 2009-10-01
JP5215290B2 (ja) 2013-06-19
WO2007127347A2 (en) 2007-11-08
WO2007127347A3 (en) 2008-01-03
EP2048954A2 (en) 2009-04-22
AU2007243252B2 (en) 2013-06-20
AU2007243252A1 (en) 2007-11-08
EP2048954A4 (en) 2009-12-02
ES2384736T3 (es) 2012-07-11
US8436160B2 (en) 2013-05-07
US20090312401A1 (en) 2009-12-17
EP2048954B1 (en) 2012-03-28
NZ572350A (en) 2011-12-22

Similar Documents

Publication Publication Date Title
CL2020000252A1 (es) Muteínas de interleucina 21 y métodos de tratamiento.
ECSP20025070A (es) Proteínas trispecificas y métodos de uso
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
CY1110536T1 (el) Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii και σχετικο αντικαρκινικο εμβολιο
BR112021022874A2 (pt) Proteínas de ligação epcam e métodos de uso
CO6270367A2 (es) Genes de dc-sign icam-3 y lsectin porcinas y usos de los mismos
UY31280A1 (es) Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
AR059257A1 (es) Genes para mejorar la eficiencia de la utilizacion de nitrogeno en los cultivos
MX338294B (es) Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales.
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
AR087091A1 (es) Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso
RU2011146048A (ru) Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
PE20130324A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
MX2022004345A (es) Construcciones de igf2 variantes.
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
ATE494381T1 (de) Verbesserte expressionselemente
BR112021017853A2 (pt) Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii
MX2020013901A (es) Virus oncolítico o antígeno que presenta terapia contra el cáncer mediada por células usando interferón tipo i y lingado de cd40.
MX2022005670A (es) Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn.
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
AR053246A1 (es) Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales

Legal Events

Date Code Title Description
FG Grant, registration